Data from a three-day Phase 2 clinical trial offered positive results for nebulized ensifentrine (RPL544) as an add-on treatment for chronic obstructive pulmonary disease (COPD), its developer Verona Pharma announced. Ensifentrine is an inhibitor of phosphodiesterase (PDE) proteins PDE3 and PDE4, which are involved in smooth muscle contraction and immune cell-derived inflammation, respectively.

The U.S. Food and Drug Administration (FDA) approved a new label for Stiolto Respimat (a combination therapy of tiotropium bromide and olodaterol) based on data from clinical trials showing a significant reduction in the frequency of chronic obstructive pulmonary disease (COPD) exacerbations driven by tiotropium, the active ingredient of …

Verona Pharma has started a Phase 2 clinical trial to evaluate the potential of its nebulized RPL554 as an add-on treatment to the approved Stiolto Respimat (tiotropium bromide/olodaterol) for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). A total of 75 patients are expected to…

GlaxoSmithKline (GSK) and Innoviva recently presented positive results of a study showing that Anoro Ellipta is more effective than Stiolto Respimat in symptomatic patients with chronic obstructive pulmonary disease (COPD). The results were presented at the 2017 CHEST Annual Meeting of the American College of Chest Physicians in Toronto, Canada,…

Boehringer Ingelheim Pharmaceuticals and Ashfield Healthcare have launched a new and free patient support program. Called ‘STIOLTO Promise,’ the no-cost offer provides 30 days of medicine, resources, and at-home counseling via respiratory specialists for patients with chronic obstructive pulmonary disease (COPD) who are prescribed STIOLTO RESPIMAT. STIOLTO RESPIMAT was approved in May 2015 for…

The U.S. Food and Drug Administration (FDA) recently approved a Supplemental New Drug Application (sNDA) for Boehringer Ingelheim Pharmaceuticals Inc.‘s Stiolto Respimat, adding data to the product’s labeling to reflect its demonstrated capacity to improve health-related quality of life in people with chronic obstructive pulmonary disease (COPD). Data came from Phase 3 clinical trials, OTEMTO…

Boehringer Ingelheim Pharmaceuticals, Inc., recently released data showing that Stiolto Respimat (inhalation spray) improved lung function over a range of measures in patients with chronic obstructive pulmonary disease (COPD), when compared to a European formulation of a long-acting beta agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate). Stiolto Respimat was approved…

During the recent American College of Chest Physicians Annual Meeting (CHEST 2015) in Montreal, Canada, Boehringer Ingelheim Pharmaceuticals, Inc. presented several positive post-hoc analyses from the TONADO® 1&2 and OTEMTO® 1&2 clinical trials. Phase III TONADO 1&2 (NCT01431274/NCT01431287) and OTEMTO® 1&2 studies evaluated the efficacy and safety of tiotropium/olodaterol delivered via the…

Boehringer Ingelheim recently announced the completion of the phase IIIb OTEMTO® 1 & 2 trials for their pipeline drug STIOLTO RESPIMAT, and have published the study data online in the Respiratory Medicine journal.  The new data reveals that the drug has the potential to improve clinical outcomes in patients with…